Dupixent (dupilumab) is an injection administered under the skin (subcutaneous ... guidance of a healthcare professional and can be given in a clinic or at home after training by a healthcare ...

Dupixent (dupilumab) is an injection administered under the skin (subcutaneous ... guidance of a healthcare professional and can be given in a clinic or at home after training by a healthcare ...

Dupixent is an injection administered under the skin (subcutaneous injection ... guidance of a healthcare professional and can be given in a clinic or at home after training by a healthcare ...

Dupixent is an injection administered under the skin (subcutaneous injection ... guidance of a healthcare professional and can be given in a clinic or at home after training by a healthcare ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria. The approval is for patients 12 years and ...

SINGAPORE, May 14, 2025 /PRNewswire/ -- The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive ...

After the first dose, it's given every two weeks under a doctor's guidance, either in a clinic or at home after training. For children ages 12 to 17, an adult should supervise the shots. Dupixent ...

SINGAPORE, May 14, 2025 /PRNewswire/ -- The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (“CSU”) in adults and adolescents aged 12 years ...

In 2024, Dupixent sales came in at $14.1 billion, which was an increase of 22% from 2023. Dupixent’s trajectory contributed heavily to Sanofi’s strong quarterly performance.